Literature DB >> 3139707

Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study.

M M Brett1, A T Ghoneim, J M Littlewood.   

Abstract

Immunoglobulin G (IgG) antibodies to Pseudomonas aeruginosa surface antigens in serum were estimated by enzyme-linked immunosorbent assay for all patients from whom P. aeruginosa was isolated for the first time during a study period of 3 years (33 patients). The titer of IgG antibodies was greater than control values at or up to 24 months before the first isolation of P. aeruginosa in 24 patients. Another five patients had titers that were within the control range before isolation of P. aeruginosa but increased to above the control range within the following 2 months. In these 29 patients, continuing intermittent isolations of P. aeruginosa were accompanied by further increases in titer. The presence of a systemic immune response above the control range indicates tissue invasion and hence infection. Four patients were deemed to have no infection: one or two isolations of P. aeruginosa were accompanied by no increase in specific antibodies to above the control range throughout the entire study period. Fifteen patients received intravenous antipseudomonal chemotherapy. Eradication of the organism and a return of titer to control values, suggesting complete removal of the organisms, occurred in 5 patients, while continued isolations and only a partial decrease in titer occurred in 10 patients. The 15 patients who received treatment improved clinically, in contrast to untreated patients, whose clinical state worsened during the study period. Continuous steroid treatment, given to two patients, was accompanied by a dramatic decrease in both serum IgG concentration and titer, despite continuing intermittent isolations of P. aeruginosa. These results confirm and extend our earlier finding that this assay appears to detect P. aeruginosa infection at a very early stage and helps in differentiating between early infection and harmless colonization. It also appears to be a useful monitor of the progress of infection and the response to intravenous antibiotic treatment in these early stages of infection, before any clinical changes are sufficiently large to be detected, in patients who were not on continuous steroid therapy. The effect of steroid treatment on the immunological response and clinical outcome of patients with early P. aeruginosa infection requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139707      PMCID: PMC266661          DOI: 10.1128/jcm.26.8.1565-1570.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1986-11       Impact factor: 3.791

2.  Development of enzyme linked immunosorbent assay (ELISA) to detect antibodies to Pseudomonas aeruginosa cell surface antigens in sera of patients with cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood; M S Losowsky
Journal:  J Clin Pathol       Date:  1986-10       Impact factor: 3.411

3.  Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71.

Authors:  M B Mearns; G H Hunt; R Rushworth
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

4.  Monoclonal antibodies against Pseudomonas aeruginosa outer membrane antigens: isolation and characterization.

Authors:  R E Hancock; A A Wieczorek; L M Mutharia; K Poole
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

Review 5.  Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.

Authors:  G B Pier
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

6.  Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression.

Authors:  J E Pennington; M G Ehrie
Journal:  J Infect Dis       Date:  1978-06       Impact factor: 5.226

7.  Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1987-04       Impact factor: 3.791

8.  Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

Authors:  H S Auerbach; M Williams; J A Kirkpatrick; H R Colten
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

9.  Dose-dependent effect of glucocorticosteroids on pulmonary defenses in a steroid-resistant host.

Authors:  L L Blackwood; J E Pennington
Journal:  Am Rev Respir Dis       Date:  1982-12

10.  Outer membrane proteins of Pseudomonas aeruginosa serotype strains.

Authors:  L M Mutharia; T I Nicas; R E Hancock
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226

View more
  16 in total

1.  Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

Review 2.  Microbiology of cystic fibrosis lung infections: themes and issues.

Authors:  J R Govan; J W Nelson
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

3.  Antibody response of fibrocystic patients to homologous 0-typable and 0-defective isolates of Pseudomonas aeruginosa.

Authors:  J MacDougall; M E Hodson; T L Pitt
Journal:  J Clin Pathol       Date:  1990-07       Impact factor: 3.411

4.  Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population.

Authors:  G A Tramper-Stranders; C K van der Ent; M G Slieker; S W J Terheggen-Lagro; F Teding van Berkhout; J L L Kimpen; T F W Wolfs
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

Review 5.  Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis.

Authors:  Lil Breen; Nivedita Aswani
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

6.  Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M Kappler; A Kraxner; D Reinhardt; B Ganster; M Griese; T Lang
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

7.  Immunoproteomics to examine cystic fibrosis host interactions with extracellular Pseudomonas aeruginosa proteins.

Authors:  Hamish G Upritchard; Stuart J Cordwell; Iain L Lamont
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

Review 8.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

9.  Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; F Espersen; C Koch
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

10.  Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.

Authors:  G Kronborg; A Fomsgaard; C Galanos; M A Freudenberg; N Høiby
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.